A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

J1O-MC-JZHB -

The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Small Cell Lung Cancer
What the trial is testing?
Erbumine
Could I receive a Placebo?
No
Enrollment Goal
48
Trial Dates
Jul 16, 2019 - Mar 30, 2021
How long will I be in the trial?
Your participation in this trial could last up to 20 months, depending on how you and your tumor respond.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have histological or cytological evidence of a diagnosis of platinum sensitive small cell lung cancer that is extensive stage

  • Participants must have adequate organ function

  • Participants must have a performance status (PS) of 1 on the Eastern Cooperative Oncology Group (ECOG) scale

  • Participants must have discontinued previous treatments for cancer.

  • Participants must be able to swallow capsules

Participants Must Not:

  • Participants must not be currently enrolled in a clinical study

  • Participants must not have a serious concomitant systemic disorder

  • Participants must not have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C

  • Participants must not have a significant cardiac condition

  • Participants must not have previously received an aurora kinase inhibitor

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.